Targeted combo aims to spare some breast cancer patients from harsher chemo
NCT ID NCT07271992
Summary
This study is testing a new, less intensive treatment approach for early triple-negative breast cancer (TNBC). It combines two targeted drugs to see if they can effectively shrink tumors before surgery for patients selected by specific tumor markers. The goal is to see if this gentler treatment can work well for the right patients, potentially reducing side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC - TRIPLE-NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.